According to a commentary, this study will lead to the welcome availability of a more convenient once weekly dosing schedule, and represents an important milestone for future research employing once weekly carfilzomib in multiagent protocols, which are becoming the standard of care for treating multiple myeloma. It notes some questions, however, remain to be answered, such as whether once weekly carfilzomib is also linked to improved overall survival. It adds that based on ENDEAVOR, the current standard dose for twice weekly carfilzomib with dexamethasone is 56 mg/m2, and it remains to be established how this compares with a dose of 70 mg/m2 once a week. It questions whether the dose difference actually matters for an irreversibly binding proteasome inhibitor. It calls for further studies to establish standard carfilzomib doses and administration schedules for combinations therapies for relapsed multiple myeloma. In meantime, clinicians will need to rely on careful scrutiny of adverse event profiles in patient subgroups, as well as reports of real-world experience.